The Accelerating Medicines Partnership, announced Tuesday by the National Institutes of Health, includes these participants:
DRUGMAKERS: AbbVie Inc., Biogen Idec Inc., Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Johnson & Johnson, Eli Lilly and Co., Merck & Co., Pfizer Inc., Sanofi SA and Takeda Pharmaceutical Co.
NONPROFIT FOUNDATIONS: Alzheimer's Association, American Diabetes Association, Foundation for the NIH, Geoffrey Beene Foundation (supports early medical research), Lupus Foundation of America, Rheumatology Research Foundation and USAgainstAlzheimer's
INDUSTRY TRADE GROUP: Pharmaceutical Research and Manufacturers of America
BEIJING (Reuters) - A woman in China has died of the H10N8 strain of bird flu, the first ever reported human case of the virus, the World Health Organisation (WHO) said on Wednesday.
The 73-year-old woman died from the virus on December 6, six days after contracting the disease, the WHO said in a statement.
Celldex has flipped Dendreon's biological model on its head. With a goal of specifically and efficiently targeting a subset of immune cells in vivo, Celldex designed antibodies that bind to the internalization receptor (the DEC-205 receptor) on APCs, and are also tethered to the cancer antigen. The APC internalizes the antibody/antigen complex, and can then signal to T-cells to begin the assault on cancerous tissue. This method has the benefits of classical vaccines, as well as the specificity and efficiency of Dendreon's Provenge, with a fraction of the cost.
A Promising Platform for Cancer Immunotherapy - BMY, CLDX, DNDN, MRK - Foolish Blogging Network
- ▼ 2014 (4)
- ► 2013 (23)
- ► 2008 (24)
- ► 2007 (65)
- ► 2006 (77)